A healthcare startup that wants to offer personalized treatments for depression just used this presentation to raise $14 million
This story is available exclusively to Business Insider subscribers. Become an Insider and start reading now.
- People with depression often go through trial and error to find treatments that work best for them.
- The German biotech company HMNC believes there’s a better way to approach depression.
- It just raised $14 million from investors to follow through on its strategy.
When a patient is sick, doctors can run tests to help determine what’s making them ill — and how to make them better.
The German biotech company HMNC Brain Health is looking to do something similar in psychiatry. It’s developing drugs geared toward patients who take tests — namely, blood draws that will undergo a genomic analysis, or an examination of the patient’s genetic makeup — to determine whether they would be a good fit for a specific kind of treatment.
Companies focused on treating mental illnesses are beginning to look at how biomarkers, or measurements like brain waves or proteins in blood samples, could help them develop drugs geared toward subtypes of an illness like depression. This could help clinicians match patients to their optimal treatments.
HMNC announced Thursday that it had raised 14.3 million euros, or about $14 million, from investors like Josef Ackermann, a former CEO of Deutsche Bank; Wilhelm Beier, the founder of the German pharmaceutical company Dermapharm; and the German soccer player Toni Kroos. The company has raised a total of 42.3 million euros.
“We believe that what is standard in oncology has to become the standard in psychiatry,” Max Döbler, HMNC’s chief business officer, told Insider.
Döbler said that medication for mental illnesses should become more precisely targeted to patients’ diseases, in the same way that cancer treatments have in recent years.